Testing a targeted treatment approach for early psychosis

This trial is testing whether clozapine—a medication that works differently than standard antipsychotics—is more helpful for people experiencing their first episode of psychosis when selected based on three specific genetic and brain markers. The study uses blood tests and a brain scan to identify patients most likely to benefit from this medication while avoiding serious side effects. Researchers believe that matching the right medication to the right patient's biology from the start could lead to better outcomes.

Many people with early psychosis don't respond well to standard antipsychotic medications, and finding the right treatment quickly is crucial. This trial exists to see if using genetic and brain imaging information upfront to personalize medication choice—rather than using a one-size-fits-all approach—can help more patients recover and avoid unnecessary side effects.